Skip to main content

Table 1 Characteristics of the SSc patients (n = 36)

From: 18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study

  No. with available data SSc patients (n = 36)
Demographics
 Sex, female, no. (%) 36 20 (55.6)
 Age, years, mean ± SD 36 57.9 ± 13.0
 Ethnical, no. (%) 33  
  White   30 (90.9)
  Black   2 (6.1)
  Asian   1 (3.1)
 BMI, kg/m2, mean ± SD 36 25.3 ± 5.9
Disease characteristics
 Cutaneous subset, limited, no. (%) 36 19 (52.8)
 Disease duration, no. (%) 36  
  < 2 years   14 (38.9)
  2–4 years   8 (22.2)
  > 4 years   14 (38.9)
 Antibody status, no. (%) 36  
  Anti-nuclear   34 (94.4)
  Anti-centromere   12 (33.3)
  Anti-topoisomerase I   10 (27.8)
  Anti-ARN polymerase III   4 (11.1)
Organ involvement, no. (%)
 Lung, no. (%)
  Interstitial lung disease 36 22 (61.1)
  Current %FVC, median (IQR) 34 90.0 (80.0; 100.0)
  Current %DLCO, median (IQR) 32 60.0 (40.0; 70.0)
 Osteoarticular 32 14 (43.8)
 Muscle 24 6 (25.0)
 Current mRSS, median (IQR) 33 12 (4.0; 21.0)
 Gastrointestinal tract 36 24 (66.7)
 Pulmonary hypertension 36 8 (22.2)
 Renal crisis 36 0 (0.0)
 Calcinosis 33 4 (12.1)
 Telangiectasia 35 22 (62.9)
 Ulcer digital 34 10 (29.4)
 Heart 36 6 (16.7)
Current treatment, no. (%)
 Steroids 36 13 (36.1)
 Immunosuppressive drugs 36 13 (36.1)
  1. BMI body mass index, %DLCO diffusing capacity for the lung of carbon monoxide (% predicted value), %FVC forced vital capacity (% predicted value), IQR interquartile range, SD standard deviation, SSc systemic sclerosis